Oncopeptides AB Statistics

Total Valuation

Oncopeptides AB has a market cap or net worth of SEK 324.50 million. The enterprise value is 191.65 million.

Market Cap	324.50M
Enterprise Value	191.65M

Important Dates

The next estimated earnings date is Friday, February 21, 2025.

Earnings Date	Feb 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Oncopeptides AB has 215.19 million shares outstanding. The number of shares has increased by 50.76% in one year.

Current Share Class	n/a
Shares Outstanding	215.19M
Shares Change (YoY)	+50.76%
Shares Change (QoQ)	+36.12%
Owned by Insiders (%)	0.82%
Owned by Institutions (%)	17.45%
Float	182.21M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.58
PB Ratio	2.39
P/TBV Ratio	2.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.68
EV / Sales	7.08
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.78

Financial Position

The company has a current ratio of 6.25, with a Debt / Equity ratio of 0.86.

Current Ratio	6.25
Quick Ratio	6.16
Debt / Equity	0.86
Debt / EBITDA	n/a
Debt / FCF	-0.48
Interest Coverage	-38.99

Financial Efficiency

Return on equity (ROE) is -209.92% and return on invested capital (ROIC) is -70.95%.

Return on Equity (ROE)	-209.92%
Return on Assets (ROA)	-57.08%
Return on Capital (ROIC)	-70.95%
Revenue Per Employee	342,671
Profits Per Employee	-3.57M
Employee Count	57
Asset Turnover	0.09
Inventory Turnover	0.84

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -72.83% in the last 52 weeks. The beta is -0.39, so Oncopeptides AB's price volatility has been lower than the market average.

Beta (5Y)	-0.39
52-Week Price Change	-72.83%
50-Day Moving Average	1.74
200-Day Moving Average	2.55
Relative Strength Index (RSI)	39.55
Average Volume (20 Days)	557,338

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Oncopeptides AB had revenue of SEK 27.07 million and -282.39 million in losses. Loss per share was -2.07.

Revenue	27.07M
Gross Profit	24.35M
Operating Income	-280.49M
Pretax Income	-280.70M
Net Income	-282.39M
EBITDA	-277.72M
EBIT	-280.49M
Loss Per Share	-2.07

Full Income Statement

Balance Sheet

The company has 250.01 million in cash and 117.16 million in debt, giving a net cash position of 132.85 million or 0.62 per share.

Cash & Cash Equivalents	250.01M
Total Debt	117.16M
Net Cash	132.85M
Net Cash Per Share	0.62
Equity (Book Value)	135.66M
Book Value Per Share	0.63
Working Capital	243.07M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -244.47 million and capital expenditures -116,000, giving a free cash flow of -244.58 million.

Operating Cash Flow	-244.47M
Capital Expenditures	-116,000
Free Cash Flow	-244.58M
FCF Per Share	-1.14

Full Cash Flow Statement

Margins

Gross Margin	89.96%
Operating Margin	-1,036.11%
Pretax Margin	-1,036.90%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Oncopeptides AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-50.76%
Shareholder Yield	-50.76%
Earnings Yield	-137.56%
FCF Yield	-75.37%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Oncopeptides AB has an Altman Z-Score of 0.55. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.55
Piotroski F-Score	n/a